ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
End-stage renal disease due to atypical hemolytic–uremic syndrome developed in a woman at 25 years of age. At 30 years of age, after 5 years of undergoing dialysis, she received a cadaveric renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results